March 06, 2006

How one drug is sizing up

Considering how many investment magazines and firms write Tysabri up as money-growing-on-the-tree drug (due to the fact there is not any very good existing/competing therapy), I'm very suspicious of the powerful wishful thinking out there. You's not just people who have MS who are hopeful--it's a larger community of investors who watch drugs in order to make money // not to mention Biogen // trying to stay profitable.

There is more information on side effects suddenly available too. I think the list of problems has to be carefully read by anyone considering Tysabri. Now I'm betting that we who live with all sorts of odds and ends of problems are not going to be interested in taking on extras in order to have one less exacerbation every 3 years. But we'll see.

No comments: